Megestrol acetate for treatment of anorexia-cachexia syndrome

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 7, 2013, Pages

  Ruiz Garcia, Vicente ^a   López Briz, Eduardo ^a   Carbonell Sanchis, Rafael ^b   Gonzalvez Perales, Jose Luis ^c   Bort Marti, Sylvia ^d  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b Hospital of Sagunt   (Spain)

^c National Health Service   (Spain)

^d Acella Incubator   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MEGESTROL ACETATE; PLACEBO; APPETITE STIMULANT;

ABDOMINAL DISEASE; ABDOMINAL PAIN; ADULT; AGED; AMENORRHEA; ANOREXIA; ANOREXIA CACHEXIA SYNDROME; APPETITE DISORDER; BEHAVIOR DISORDER; BULLOUS SKIN DISEASE; CACHEXIA; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFUSION; CONSTIPATION; COORDINATION DISORDER; DEPRESSION; DIARRHEA; DROWSINESS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FEMALE; GLUCOSE INTOLERANCE; HALLUCINATION; HEADACHE; HEART FAILURE; HEARTBURN; HUMAN; HYPERPHAGIA; HYPERTENSION; HYPERTRANSAMINASEMIA; IMPOTENCE; INCREASED APPETITE; INFECTION; INSOMNIA; INTESTINE OBSTRUCTION; LEG EDEMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MENSTRUAL IRREGULARITY; NAUSEA; NEOPLASM; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; REVIEW; SKIN DISEASE; SWEATING; SYSTEMATIC REVIEW; TESTIS DISEASE; THORAX PAIN; THROMBOEMBOLISM; THROMBOPHLEBITIS; VOMITING; WEIGHT GAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; META ANALYSIS; SYNDROME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANOREXIA; APPETITE STIMULANTS; CACHEXIA; HUMANS; MEGESTROL ACETATE; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYNDROME;

MLCS; MLOWN;

EID: 84880061173     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004310.pub3     Document Type: Review

References (191)

1. Batterham M, Garsia R. Randomised prospective medium term comparison of megestrol acetate, nandrolone decanoate and dietary therapy alone for HIV associated weight loss [abstract]. Australasian Society for HIV Medicine 1997;9:91. 6241565
2. Batterham MJ, Garsia R. A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. International Journal of Andrology 2001;24(4):232-40. 2780245
3. Beller E, Tattersall M. Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomised placebo-controlled trial. Annals of Oncology 1997;8:277-83. 6241566
4. Casado Herráez A. Phase II randomized study of two dose levels of megestrol acetate versus placebo for the treatment of anorexia and cachexia in patients with locoregional advanced or metastatic cancer [Estudio de fase II randomizado de dos niveles posológicos de acetato de Megestrol versus placebo para el tratamiento de la anorexia y la caquexia en pacientes con cáncer locoregional avanzado o metastásico. (Tesis de Doctorado - Universidad Complutense Madrid)]. Available from http://eprints.ucm.es/8119/1/T30450.pdf 2008 (accessed 24 December 2011). 6241567
5. De Conno F, Martini C. Megestrol acetate for anorexia in patients with far-advanced cancer: a double-blind controlled clinical trial. European Journal of Cancer 1998;34:1705-9. 6241568
6. Eubanks V, Koppersmith N. Effects of megestrol acetate on weight gain, body composition, and pulmonary function in patients with cystic fibrosis. Journal of Pediatrics 2002;140:439-44. 6241569
7. Feliu J, Gonzalez-Baron M. Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo controlled study. American Journal of Clinical Oncology 1992;15:436-40. 6241570
8. Gonzalez Baron M, Feliu J, Zamora P, Artal A, Garrido P, Chacon I. Usefulness of megestrol acetate on cancer cachexia: a double blind randomized study. Annals of Oncology 1990;1:29-31. 2780256
9. Fietkau R, Riepl M. Supportive treatment with megestrol acetate during radio (chemo) therapy. A randomised trial. Strahlentherapie und Onkologie 1996;172:162-8. 6241572
10. Fietkau R, Riepl M, Kettner H, Hinke A, Sauer R. Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy. European Journal of Cancer 1997;33:75-9. [CN-00137738]6241571
11. Gambardella A, Pesce L, Bolognino P, Lombardi G, Barbieri M, Rinaldi C. Megestrol acetate prevents cachexia in elderly cancer patient. Annals of Oncology 1998;9(Suppl 3):72. [CN-00305911]2780261
12. Gambardella A, Pesce L, Lammardo AM, Lombardi G, Barbagallo M, Tirelli P, et al. New factors involvement in elderly cancer patients with anorexia/cachexia syndrome role of megestrol acetate. Annals of Oncology 2000;9 Suppl 2:22. 6241573
13. Gebbia V, Testa A. Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer. British Journal of Cancer 1996;73:1576-80. 6241574
14. Giacosa A, Frascio F, Sukkar SG, Costantini M, Baracco G, Capelli M. Changes of nutritional and psychological status after megestrol acetate treatment of cancer cachexia. Rivista Italiana Di Nutrizione Parenterale Ed Enterale. 1997;15:20-3. 6241575
15. Heckmayr M, Gatzemeier U. Treatment of cancer weight loss in patients with advanced lung cancer. Oncology 1992;49(Suppl 2):32-4. 2780268
16. Herrejon A, Catalan P, Palop J, Inchaurraga I, Blanquer R, Lopez A. Effect of 8-week 320 mg megestrol acetate daily administration in severe COPD and weight loss [Abstract]. American Journal of Respiratory and Critical Care Medicine 2010;181:A4484. 6241576
17. Herrejon A, Palop J, Inchaurraga I, Lopez A, Bañuls C, Hernandez A, et al. Low doses of megestrol acetate increase weight and improve nutrition status in patients with severe chronic obstructive pulmonary disease and weight loss. Medicina Clinica 2011;137:193-8. 6241577
18. Jatoi A, Windschitl HE. Dronabinol versus megestrol acetate versus combination for cancer-associated anorexia: A North Central Cancer Treatment Group Study. Journal of Clinical Oncology 2002;20:567-73. 6241578
19. Jatoi A, Rowland K, Loprinzi CL, Sloan JA, Dakhil SR, MacDonald N, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. Journal of Clinical Oncology 2004;22:2469-76. 6241579
20. Lesser GJ, Case D, Sharp S, Choksi J, Miller A, Atkins J, et al. A phase III randomized study comparing the effects of oxandrolone (Ox) and megestrol acetate (Meg) on weight (wt), lean body mass (LBM) and quality of life (QOL) in solid tumor patients (pts) receiving chemotherapy (chemo). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I 2006;24(18S (June 20 Suppl)):18546. 6241580
21. Loprinzi CL, Ellison NM. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. Journal of the National Cancer Institute 1990;82:1127-32. 6241582
22. Loprinzi CL, Bernath AM. Phase III evaluation of 4 doses of megestrol acetate for patients with cancer anorexia and/or cachexia. Oncology 1994;51:2-7. 6241583
23. Loprinzi CL, Michalak JC, Schaid DJ, Mailliard JA, Athmann LM, Goldberg RM, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. Journal of Clinical Oncology 1993;11:762-7. [CN-00092689]6241584
24. Loprinzi CL, Kugler J, Sloan J, Mailliard J, Krook J, Wilwerding M, et al. Phase III randomized comparison of megestrol acetate, dexamethasone, and fluoxymesterone for the treatment of cancer anorexia/cachexia [Meeting abstract no 167]. ASCO Annual Meeting. 1997. 6241586
25. Loprinzi CL, Kugler JW. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology 1999;17:3299-306. 6241587
26. Loprinzi CL, Kugler J, Sloan J, Mailliard J, Krook J, Wilwerding M, et al. Phase III randomized comparison of megestrol acetate, dexamethasone, and fluoxymesterone for the treatment of cancer anorexia/cachexia [Meeting abstract no 167]. ASCO Annual Meeting. 1997. 6241589
27. Loprinzi CL, Kugler JW. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology 1999;17:3299-306. 6241590
28. Macbeth FR, Grgeor A, Cott. A randomised study of megestrol acetate (MA) and prednisolone (P) for anorexia and weight loss in patients with lung cancer. Lung Cancer 1994;1 Suppl 1:88. 6241591
29. Madeddu C, Dessì M, Panzone F, Serpe R, Antoni G, Cau MC, et al. Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib ± megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. Clinical Nutrition 2012;31:176-82. 6241592
30. McMillan DC, Simpson JM. Effect of megestrol acetate on weight loss, body composition and blood screen of gastrointestinal cancer patients. Clinical Nutrition 1994;13:85-9. 6241593
31. Mwamburi DM, Gerrior J, Wilson IB, Chang H, Scully E, Saboori S, et al. Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar results in 2 months. Clinical Infectious Diseases 2004;38:895-902. 6241594
32. Oster MH, Enders SR. Megestrol acetate in patients with AIDS and cachexia. Annals of Internal Medicine 1994;121:400-8. 6241595
33. Sancho-Cuesta JF. Megestrol acetate and weight loss in advanced cancer [Abstract no: 1141]. European Journal of Cancer 1993;29A:S204. 2780304
34. Schmoll E, Wilke H, Thole R, Preusser P, Wildfang I, Schmoll HJ. Megestrol acetate in cancer cachexia. Seminars in Oncology 1991;18(1 Suppl 2):32-4. [CN-00072963]2780306
35. Schmoll E. Risks and benefits of various therapies for cancer anorexia. Oncology 1992;49:43-5. 6241596
36. Summerbell CD, Youle M, McDonald V, Catalan J, Gazzard BG. Megestrol acetate vs cyproheptadine in the treatment of weight loss associated with HIV infection. International Journal of STD and AIDS 1992;3:278-80. 6241597
37. Tchekmedyian NS, Hickman M. Megestrol acetate in cancer anorexia and weight loss. Cancer 1992;69:1268-74. 6241598
38. Timpone JG, Wright DJ. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Research and Human Retroviruses 1997;13:305-15. 6241599
39. Ulutin HC, Arpaci F, Pak Y. Megestrol acetate for cachexia and anorexia in advanced non-small cell lung cancer: a randomized study comparing two different doses. Tumori 2002;88:277-80. 6241600
40. Segui MA, Vadell C, Gimenez-Arnau JM, Morales S, Cirera L, Bestit I, et al. Double-blind randomized trial for the treatment of cancer related cachexia: comparison of placebo vs two different doses of megestrol acetate [Abstract 99]. Proceedings of the American Society of Clinical Oncology 1996;15:529. 2780318
41. Vadell C, Segui MA. Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. American Journal of Clinical Oncology 1998;21:347-51. 6241601
42. Von Roenn JH, Armstrong D. Megestrol acetate in patients with AIDS-related cachexia. Annals of Internal Medicine 1994;121:393-9. 6241602
43. Cilla DD, Gutierrez JL, Kristensen A, Kramer LD. The safety of megestrol acetate concentrated suspension (MA-CS) and megestrol acetate oral suspension (MA-OS) in a pilot study in patients with HIV-associated unintended weight loss (UWL) [Abstract]. Blood 2006;108:43. 6241603
44. Wanke C, Gutierrez J, Kristensen A, MacEarchern, L. Safety and efficacy of two preparations of megestrol acetate in HIV-infected individuals with weight loss in Africa, India, and the United States. Journal of Applied Research 2007;7:206-16. 6241604
45. Weisberg J, Wanger J. Megestrol acetate stimulates weight gain and ventilation in underweight COPD patients. Chest 2002;121(4):1070-8. 2780326
46. Yeh SS, Lovitt S, Schuster MW. Usage of megestrol acetate in the treatment of anorexia-cachexia syndrome in the elderly. Journal of Nutrition, Health and Aging 2009;13:448-54. 6241605
47. Yeh SS, Wu SY. Improvement in quality of life measures and stimulation of weight gain after treatment with megestrol acetate oral suspension in geriatric cachexia: results of a double-blind, placebo-controlled study. Journal of the American Geriatrics Society 2000;48(5):485-92. 2780331
48. Yeh SS, Wu SY, Levine DM, Parker TS, Olson JS, Stevens MR, et al. The correlation of cytokine levels with body weight after megestrol acetate treatment in geriatric patients. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 2001;56:M48-54. 6241606
49. Aguilera A, Selgas R, Diez JJ, Bajo MA, Codoceo R, Alvarez V. Anorexia in end-stage renal disease: pathophysiology and treatment. Expert Opinion on Pharmacotherapy 2001;2(11):1825-38. 6241608
50. Aisner J, Tchekmedyian NS, Tait N, Parnes H, Novak M. Studies of high-dose megestrol acetate: potential applications in cachexia. Seminars in Oncology 1988;15(2 Suppl 1):68-75. 6241610
51. Anonymous. Megestrol found effective in two trials. AIDS Patient Care 1995;9(1):41. 6241612
52. Ansfield FJ, Kallas GJ, Singson JP. Clinical results with megestrol acetate in patients with advanced carcinoma of the breast. Surgery, Gynecology & Obstetrics 1982;155(6):888-90. 2780333
53. Argiles JM, Lopez-Soriano FJ, Busquets S. Emerging drugs for cancer cachexia. Expert Opinion on Emerging Drugs 2007;12(4):555-70. 6241614
54. Argiles JM, Lopez-Soriano FJ, Busquets S. Novel approaches to the treatment of cachexia. Drug Discovery Today 2008;13(1-2):73-8. 6241616
55. Argiles JM, Olivan M, Busquets S, Lopez-Soriano FJ. Optimal management of cancer anorexia-cachexia syndrome. Cancer Management and Research 2010;2(1):27-38. 6241618
56. Behl D, Jatoi A. Pharmacological options for advanced cancer patients with loss of appetite and weight. Expert Opinion on Pharmacotherapy 2007;8(8):1085-90. 6241620
57. Bossola M, Tazza L, Giungi S, Luciani G. Anorexia in hemodialysis patients: an update. Kidney International 2006;70(3):417-22. 6241622
58. Bossola M, Tazza L, Luciani G. Mechanisms and treatment of anorexia in end-stage renal disease patients on hemodialysis. Journal of Renal Nutrition 2009;19(1):2-9. 6241624
59. Bruera E, McMillan K. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990;66:1279-82. 6241625
60. Bruera E. Clinical management of anorexia and cachexia in patients with advanced cancer. Oncology 1992;49 Suppl 2:35-42. 6241627
61. Bruera E, Scott E. Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. Cancer Prevention and Control 1998;2(2):74-8. 2780337
62. Bruera E. Pharmacological treatment of cachexia: any progress? [Review]. Supportive Care in Cancer 1998;6(2):109-13. 6241629
63. Cardona D. Pharmacological therapy of cancer anorexia-cachexia. Nutricion Hospitalaria 2006;21:Suppl 26. 6241631
64. Carroll JK, Kohli S, Mustian KM, Roscoe JA, Morrow GR. Pharmacologic treatment of cancer-related fatigue. Oncologist 2007;12(Suppl 1):43-51. 6241633
65. Cat LK, Coleman RL. Treatment for HIV wasting syndrome. Annals of Pharmacotherapy 1994;28(5):595-7. 6241635
66. Celik T, Iyisoy A, Gundogdu F, Isik E. Chronic pulmonary cachexia syndrome: the role of anorexia. International Journal of Cardiology 2009;132(3):432-3. 6241637
67. Chen HC, Leung SW, Wang CJ, Sun LM, Fang FM, Hsu JH. Effect of megestrol acetate and prepulsid on nutritional improvement in patients with head and neck cancers undergoing radiotherapy. Radiotherapy and Oncology 1997;43:75-9. 6241638
68. Chlebowski RT, Palomares MR, Lillington L, Grosvenor M. Recent implications of weight loss in lung cancer management. Nutrition 1996;12(1 Suppl):S43-7. 6241640
69. Costero O, Bajo MA, del Peso G, Gil F, Aguilera A, Ros S, et al. Treatment of anorexia and malnutrition in peritoneal dialysis patients with megestrol acetate. Advances in Peritoneal Dialysis 2004;20:209-21. 6241641
70. Cruz JM, Muss HB, Brockschmidt JK, Evans GW. Weight changes in women with metastatic breast cancer treated with megestrol acetate: a comparison of standard versus high-dose therapy. Seminars in Oncology 1990;17:63-7. 6241643
71. Cuerda Compes M, Breton Lesmes I, Camblor Alvarez M, Garcia Peris P. Pharmacological modulation of the appetite. Nutricion Hospitalaria 1998;13(2):69-75. 6241645
72. Desport JC, Blanc-Vincent MP, Gory-Delabaere G, Bachmann P, Beal J, Benamouzig R, et al. Standards, Options and Recommendations (SOR) for the use of appetite stimulants in oncology. Work group. Federation of the French Cancer Centres (FNCLCC). Bulletin du Cancer 2000;87(4):315-28. 6241647
73. Elovic E. Pharmacological therapeutics in nutritional management. Journal of Head Trauma Rehabilitation 2000;15(3):962-4. 6241649
74. Erkurt E, Erkisi M, Tunali C. Supportive treatment in weight-losing cancer patients due to the additive adverse effects of radiation treatment and/or chemotherapy. Journal of Experimental & Clinical Cancer Research 2000;19:431-9. 6241650
75. Farmer M, Case D, Lesser G, Monitto D, Smathers S, May B, et al. A phase III, double blind, placebo-controlled, prospective randomized trial on the effect of megestrol acetate on weight and health related quality of life in lung cancer and head and neck cancer patients receiving curative radiation therapy. Proceedings of the American Society for Therapeutic Radiology and Oncology, 47th.Annual Meeting; 2005 Oct 16-19; Denver, Colorado, USA. International Journal of Radiation Oncology Biology Physics 2005;63:S77-8. 6241652
76. Farrar DJ. Megestrol acetate: promises and pitfalls [Review]. Aids Patient Care and STDS 1999;13(3):149-52. 6241654
77. Fearon KCH, Moses AGW. Cancer cachexia. International Journal of Cardiology 2002;85(1):73-81. 6241656
78. Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31, 510 women. Journal of Clinical Oncology 1998;16(10):3439-60. 6241658
79. Fox CB, Treadway AK, Blaszczyk AT, Sleeper RB. Megestrol acetate and mirtazepine for the treatment of unplanned weight loss in the elderly. Pharmacotherapy 2009;29(4):383-97. 6241660
80. Freyer G, Catimel G, Merrouche Y. Synthetic progestational hormones in the treatment of neoplastic cachexia. Revue de Medecine Interne 1996;17(1):79-84. 6241662
81. Freyer G, Catimel G, Merrouche Y. Progesterone derivatives in cancer cachexia. Revue de Medecine Interne 1996;17(1):79-84. 6241664
82. Gadducci A, Cosio S, Fanucchi A, Genazzani AR. Malnutrition and cachexia in ovarian cancer patients: pathophysiology and management. Anticancer Research 2011;21(4B):2941-7. 6241666
83. Garg S, Yoo J, Winquist E. Nutritional support for head and neck cancer patients receiving radiotherapy: a systematic review [Review]. Supportive Care in Cancer 2010;18(6):667-77. 6241668
84. Gullett NP, Mazurak VC, Hebbar G, Ziegler TR. Nutritional Interventions for cancer-induced cachexia. Current Problems in Cancer 2011;35:58-90. 6241670
85. Hanson LC, Ersek M, Gilliam R, Carey TS. Oral feeding options for people with dementia: a systematic review. Journal of the American Geriatrics Society 2011;59(3):463-72. 6241672
86. Haren MT, Kim MJ, Kevorkian RT. Megestrol acetate for geriatric anorexia/cachexia. Journal of the American Geriatrics Society 2006;54(1):172-3. 6241674
87. Hellerstein MK, Kahn J, Mudie H, Viteri F. Current approach to the treatment of human immunodeficiency virus-associated weight loss: pathophysiologic considerations and emerging management strategies. Seminars in Oncology 1990;17(6 Suppl 9):33. 6241676
88. Hoffman KR, Green NJ. Megestrol acetate (Megace) to prevent cachexia and marasmus in elderly cancer patients (Meeting abstract no 233). ASCO Annual Meeting. 1998. 6241677
89. Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA: A Cancer Journal for Clinicians 2002;52:72-91. 6241679
90. Jatoi A, Loprinzi CL. An update: cancer-associated anorexia as a treatment target. Current Opinion in Clinical Nutrition and Metabolic Care 2001;4(3):179-82. 6241681
91. Kalantar-Zadeh K, Anker SD, Horwich TB, Fonarow GC. Nutritional and anti-inflammatory interventions in chronic heart failure. American Journal of Cardiology 2008;101:89E-103E. 6241683
92. Karcic E, Philpot C, Morley JE. Treating malnutrition with megestrol acetate: literature review and review of our experience. Journal of Nutrition, Health, and Aging 2002;6:191-200. 6241685
93. Khojasteh A, Khojasteh S, Reynolds R. Combined nortriptyline + megestrol acetate regimen for cancer anorexia-cachexia syndrome [abstract]. Proceedings of the American Society of Clinical Oncology 1996;15:451. 6241686
94. Krznaric Z, Juretic A, Samija M, Dintinjana RD, Vrdoljak E, Samarzija M, et al. Croatian guidelines for use of eicosapentaenoic acid and megestrol acetate in cancer cachexia syndrome [Croatian]. Lijecnicki Vjesnik 2007;129:381-6. 6241688
95. Kumar NB, Kazi A, Smith T, Crocker T, Yu D, Reich RR, et al. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Current Treatment Options in Oncology 2010;11:107-17. 6241690
96. Lai YL, Fang FM, Yeh CY. Management of anorexic patients in radiotherapy: a prospective randomized comparison of megestrol and prednisolone. Journal of Pain and Symptom Management 1994;9:265-8. 6241691
97. Lelli G, Montanari M, Gilli G, Scapoli D, Antonietti C, Scapoli D. Treatment of the cancer anorexia-cachexia syndrome: a critical reappraisal. Journal of Chemotherapy 2003;15:220-5. 6241693
98. Lesniak W, Bala M, Jaeschke R, Krzakowski M. Effects of megestrol acetate in patients with cancer anorexia-cachexia syndrome--a systematic review and meta-analysis. Polskie Archiwum Medycyny Wewnetrznej 2008;118:636-44. 6241695
99. Loprinzi CL, Goldberg RM, Burnham NL. Cancer-associated anorexia and cachexia. Implications for drug therapy. Drugs 1992;43:499-506. 6241697
100. Loprinzi CL, Johnson PA, Jensen M. Megestrol acetate for anorexia and cachexia. Oncology 1992;49 Suppl 2:46-9. 6241699
101. Loprinzi CL, Schaid DJ, Dose AM, Burnham NL, Jensen MD. Body-composition changes in patients who gain weight while receiving megestrol acetate. Journal of Clinical Oncology 1993;11:152-4. 6241700
102. Loprinzi CL. Management of cancer anorexia/cachexia. Supportive Care in Cancer 1995;3:120-2. 6241702
103. Mak RH, Cheung W. Therapeutic strategy for cachexia in chronic kidney disease. Current Opinion in Nephrology and Hypertension 2007;16:542-6. 6241704
104. Malone M. Medications associated with weight gain. Annals of Pharmacotherapy 2005;39:2046-55. 6241706
105. Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. Annals of Oncology 2001;12:289-300. 6241708
106. Mantovani G, Maccio A, Lai P, Massa E, Ghiani M, Santona MC. Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. Critical Reviews in Oncogenesis 1998;9:99-106. 6241710
107. Mantovani G, Maccio A, Massa E, Madeddu C. Managing cancer-related anorexia/cachexia. Drugs 2001;61:499-514. 6241712
108. Mantovani G, Macciò A, Madeddu C, Gramignano G, Serpe R, Massa E, et al. Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. Nutrition 2008;24:305-13. 6241713
109. Mantovani G, Maccio A, Madeddu C, Serpe R, Massa E, Dessi M, et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 2010;15:200-11. 6241714
110. Marchand V, Baker SS. Randomized, double-blind, placebo-controlled pilot trial of megestrol acetate in malnourished children with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 2000;31:264-9. 6241715
111. Mateen F, Jatoi A. Megestrol acetate for the palliation of anorexia in advanced, incurable cancer patients. Clinical Nutrition 2006;25:711-5. 6241717
112. McHugh ME, Miller-Saultz D. Assessment and management of gastrointestinal symptoms in advanced illness. Primary Care 2011;38:225-46. 6241719
113. McMillan DC, Wigmore SJ. A prospective randomised study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. British Journal of Cancer 1999;79:495-500. 6241720
114. McQuellon RP, Moose DB, Russell GB, Case LD, Greven K, Stevens M, et al. Supportive use of megestrol acetate (Megace) with head/neck and lung cancer patients receiving radiation therapy. International Journal of Radiation Oncology, Biology, Physics 2002;52:1180-5. 6241721
115. Monfared A, Heidarzadeh A, Ghaffari M, Akbarpour M. Effect of megestrol acetate on serum albumin level in malnourished dialysis patients. Journal of Renal Nutrition 2009;19:167-71. 6241722
116. Morán S, Ortega R, Garcia G, Uribe M. Megestrol acetate improve appetite and induce anti-catabolic effect in post-hepatitis C cirrhotic patients. A double-blind placebo-controlled clinical trial [Abstract 80]. Hepatology 1998;28:609A. 6241723
117. Morley JE. Orexigenic and anabolic agents. Clinics in Geriatric Medicine 2002;18:853-66. 6241725
118. Mulligan K, Zackin R, Von-Roenn JH, Chesney MA, Egorin MJ, Sattler FR, et al. Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. Journal of Clinical Endocrinology and Metabolism 2007;92:563-70. 6241726
119. Muss HB, Case LD, Capizzi RL, Cooper MR, Cruz J, Jackson D, et al. High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association. Journal of Clinical Oncology 1990;8:1797-805. 6241727
120. Navari RM, Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Supportive Care in Cancer 2010;18:951-6. 6241728
121. Nelson KA, Walsh D, Hussein M. A phase II study of low-dose megestrol acetate using twice-daily dosing for anorexia in nonhormonally dependent cancer. American Journal of Hospice and Palliative Care 2002;19:206-10. 6241729
122. Osoba D, Murray N, Gelmon K, Karsai H, Knowling MA, Shah A, et al. Phase II trial of megestrol in the supportive care of patients receiving dose-intensive chemotherapy. Oncology 1994;8:43-9. 6241730
123. Pardo J, Mena AM, Montsech L. Megestrol acetate for anorexia in lung cancer patients undergoing radiation therapy. A randomized trial comparing the efficacy of two different doses in 130 patients [Abstract 3076]. Proceedings of the American Society of Clinical Oncology 2003;22:765. 6241732
124. Pardo J, Mena A, Monleon A, Macias V, Sole J, Hernandez M, et al. Reversal of anorexia with megestrol acetate (MA): impact on quality of life (QoL) in non-metastatic lung cancer patients (pts) undergoing radiation therapy. Journal of Clinical Oncology 2006;24:18613. 6241733
125. Pascual Lopez A, Figuls M, Urrutia Cuchi G, Berenstein EG, Almenar Pasies B, Balcells Alegre M, et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. Journal of Pain and Symptom Management 2004;27:360-9. 6241735
126. Pruthi S, Boughey JC, Brandt KR, Degnim AC, Dy GK, Goetz MP, et al. A multidisciplinary approach to the management of breast cancer, part 2: Therapeutic considerations. Mayo Clinic Proceedings 2007;82:1131-40. 6241737
127. Reuben DB, Hirsch SH, Zhou K, Greendale GA. The effects of megestrol acetate suspension for elderly patients with reduced appetite after hospitalization: a phase II randomized clinical trial. Journal of the American Geriatrics Society 2005;53:970-5. 6241738
128. Ross DD, Alexander CS. Management of common symptoms in terminally ill patients: Part I. Fatigue, anorexia, cachexia, nausea and vomiting. American Family Physician 2001;64:807-14. 6241740
129. Rowland KM, Loprinzi CL. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group Study. Journal of Clinical Oncology 1996;14:135-41. 6241741
130. Ruiz-Garcia V, Juan O, Perez Hoyos S, Peiro R, Ramon N, Rosero MA, et al. Megestrol acetate: a systematic review usefulness about the weight gain in neoplastic patients with cachexia. Medicina Clinica 2002;119:166-70. 6241742
131. Sanz-Ortiz J. Anorexia treatment in the oncological patient. Revista Clinica Espanola 2004;204:542-4. 6241744
132. Schacter L, Rozencweig M, Canetta R, Kelley S, Nicaise C, Smaldone L. Megestrol acetate: clinical experience [Review]. Cancer Treatment Reviews 1989;16:49-63. 6241746
133. Schmoll E. Risks and benefits of various therapies for cancer anorexia. Oncology 1992;49 Suppl 2:43-5. 6241748
134. Simmons SF, Walker KA, Osterweil D. The effect of megestrol acetate on oral food and fluid intake in nursing home residents: a pilot study. Journal of the American Medical Directors Association 2004;5:24-30. 6241749
135. Skarlos DV, Fountzilas G, Pavlidis N, Beer M, Makrantonakis P, Aravantinos G, et al. Megestrol acetate in cancer patients with anorexia and weight loss. A Hellenic Co-operative Oncology Group (HeCOG) study. Acta Oncologica 1993;32:37-41. 6241750
136. Spaulding M. Recent studies of anorexia and appetite stimulation in the cancer patient. Oncology 1989;3(8 Suppl):18-23. 6241752
137. Sullivan DH, Roberson PK, Smith ES, Price JA, Bopp MM. Effects of muscle strength training and megestrol acetate on strength, muscle mass, and function in frail older people. Journal of the American Geriatrics Society 2007;55:20-8. 6241753
138. Tchekmedyian NS, Tait N, Aisner J. High dose megestrol acetate in the treatment of postmenopausal women with advanced breast cancer. Seminars in Oncology 1986;13:20-5. 6241754
139. Tchekmedyian NS, Hickman M, Siau J, Greco A, Aisner J. Treatment of cancer anorexia with megestrol acetate: impact on quality of life. Oncology 1990;4:185-92. 6241755
140. Tchekmedyian NS, Hickman M, Heber D. Treatment of anorexia and weight loss with megestrol acetate in patients with cancer or acquired immunodeficiency syndrome. Seminars in Oncology 1991;18 Suppl 2:35-42. 6241757
141. Tchekmedyian NS. Clinical approaches to nutritional support in cancer. Current Opinion in Oncology 1993;5:633-8. 6241759
142. Tchekmedyian NS. Treatment of anorexia with megestrol acetate. Nutrition in Clinical Practice 1993;8:115-8. 6241761
143. Tchekmedyian NS. Treating the anorexia/cachexia syndrome. Journal of Supportive Oncology 2006;4:506-7. 6241763
144. Thomas DR. Guidelines for the use of orexigenic drugs in long-term care. Nutrition in Clinical Practice 2006;21:82-7. 6241765
145. Tisdale MJ. Cancer cachexia. Anti-Cancer Drugs 1993;4:115-25. 6241767
146. Tisdale MJ. Clinical anticachexia treatments. Nutrition in Clinical Practice 2006;21:168-74. 6241769
147. Tomíska M, Tomisková M, Salajka F, Adam Z, Vorlícek J. Palliative treatment of cancer anorexia with oral suspension of megestrol acetate. Neoplasma 2003;50:227-33. 6241770
148. Vigano A, Watanabe S, Bruera E. Anorexia and cachexia in advanced cancer patients. Cancer Surveys 1994;21:99-115. 6241772
149. von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacology & Therapeutics 2009;121:227-52. 6241774
150. Von Roenn JH. Randomized trials of megestrol acetate for AIDS-associated anorexia and cachexia. Oncology 1994;51 Suppl 1:19-24. 6241776
151. Vyzula R. Current views on use of megestrol acetate in oncology practice. Vnitrni Lekarstvi 1997;43:250-5. 6241778
152. Westman G, Bergman B, Albertsson M, Kadar L, Gustavsson G, Thaning L, et al. Megestrol acetate in advanced, progressive, hormone-insensitive cancer. Effects on the quality of life: a placebo-controlled, randomised, multicentre trial. European Journal of Cancer 1999;35:586-95. 6241779
153. Yavuzsen T, Davis MP, Walsh D, LeGrand S, Lagman R. Systematic review of the treatment of cancer-associated anorexia and weight loss. Journal of Clinical Oncology 2005;23:8500-11. 6241781
154. Yeh S, Hafner A, Chang C, Levine DM, Parker TS, Schuster MW. Risk factors relating blood markers of inflammation and nutritional status to survival in cachectic geriatric patients in a randomized clinical trial. Journal of the American Geriatrics Society 2004;52:1708-12. 6241783
155. Yeh SS, Schuster MW. Megestrol acetate in cachexia and anorexia. International Journal of Nanomedicine 2006;1:411-6. 6241785
156. Yeh SS, Lovitt S, Schuster MW. Pharmacological treatment of geriatric cachexia: evidence and safety in perspective. Journal of the American Medical Directors Association 2007;8:363-77. 6241787
157. Yeh SS, Marandi M, Thode HC, Levine DM, Parker T, Dixon T, et al. Report of a pilot, double-blind, placebo-controlled study of megestrol acetate in elderly dialysis patients with cachexia. Journal of Renal Nutrition 2010; Vol. 20:52-62. 6241788
158. Zeca E, Martini C, Venturino P, Tedeschi M, Ventafrida V, De Conno F. Efficacy of megestrol acetate on anorexia in patients with advanced non hormone-related tumors: a double-blind placebo controlled clinical trial. European Journal of Cancer 1995;31A:S261-2. [CN-00519065]6241789
159. Argilés JM, Meijsing SH, Pallares-Trujillo J. Cancer cachexia. A therapeutic approach. Medical Research Review (US) 2001;21:83-101.
160. Balog DL, Epstein ME, Amidio-Groton MI. HIV wasting syndrome: treatment update. Annals of Pharmacotherapy 1998;32(4):446-58.
161. Barber MD, Ross JA, Voss AC, Tisdale MJ, Fearon KC. The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer. British Journal of Cancer 1999;81:80-6.
162. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54:405-11.
163. Bruera E. Clinical management of anorexia and cachexia in patients with advanced cancer. Oncology 1992;49(2):35-42.
164. Campa A, Yang Z, Lai S, Xue L, Phillips JC, Sales S, et al. HIV-related wasting in HIV-infected drug users in the era of highly active antiretroviral therapy. Clinical Infectious Diseases 2005;41:1179-85.
165. Deeks J, Higgins J, Altman D. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008. Available from: www.cochrane-handbook.org.
166. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncology 2011;12:489-95.
167. Fick D, Semla T, Beizer J, Brandt N, Dombrowski R, DuBeau CE, et al. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society 2012;60(4):616-31.
168. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Chichester, UK: Wiley-Blackwell, 2011:649.
169. Jadad A, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports on randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;170:1-12.
170. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135:982-9.
171. Laird NM, Wang F. Estimating rates of change in randomized clinical trials. Controlled Clinical Trials 1990;11:405-19.
172. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. New England Journal of Medicine 1988;318:1728-33.
173. Loprinzi C, Ellison NM, Goldberg RM, Michalak JC, Burch PA. Alleviation of cancer anorexia and cachexia: studies of the Mayo Clinic and the North Central Cancer Treatment Group. Seminars in Oncology 1990;17(6 Suppl 9):8-12.
174. Loprinzi CL, Kugler JW, Sloan JA. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. Journal of Clinical Oncology 1999;17:3299-306.
175. Mangili A, Murman DH, Zampini AM, Wanke CA. Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort. Clinical Infectious Diseases 2006;42:836-42.
176. Nelson KA, Walsh D, Sheehan FA. The cancer anorexia-cachexia syndrome. Journal of Clinical Oncology 1994;12:213-25.
177. Nüesch E, Trelle S, Reichenbach S, Rutjes AW, TschannenB, Altman DG, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ 2010;341:c3515.
178. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
179. Schulz KF, Altman DG. Statistical Methods for Data Synthesis. Cochrane Workshop Report. Oxford: UK Cochrane Centre, 1993.
180. Splinter TA. Cachexia and cancer: a clinician's view. Annals of Oncology 1992;3(3):25-7.
181. Tang AM, Jacobson DL, Spiegelman D, Knox TA, Wanke CA. Increasing risk of 5% or greater unintentional weight loss in a cohort of HIV-infected patients, 1995 to 2003. Journal of Acquired Immune Deficiency Syndromes 2005;40:70-6.
182. Thompson CM, Rodgers RL. Analysis of the autopsy records of 157 cases of carcinoma of the pancreas with particular reference to the incidence of thromboembolism. American Journal of the Medical Sciences 1952;223:469-76.
183. Thompson SG, Sharp SJ. Explaining heterogeneity in meta-analysis: a comparison of methods. Statistics in Medicine 1999;18:2693-708.
184. Tisdale M. Mechanisms of cancer cachexia. Physiological Reviews 209;89:381-410.
185. Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. Journal of Clinical Oncology 2003;21:3665-75.
186. Von Roenn JH, Knopf K. Anorexia/cachexia in patients with HIV: lessons for the oncologist. Oncology 1996;10(7):1049-56.
187. Wigmore SJ, Fearon KCH, Maingay JP, Ross JA. Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Clinical Science 1997;92:215-21.
188. Wolf I, Sadetzki S, Kanety H, Kundel Y, Pariente C, Epstein N, et al. Adiponectin, ghrelin and leptin in cancer cachexia in breast and colon cancer patients. Cancer 2006;106:966-73.
189. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991;266:93-8.
190. Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858]
191. Berenstein EG, Ortiz Z. Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database of Systematic Reviews 2011, Issue 7. [DOI: 10.1002/14651858]